Literature DB >> 28146276

Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen.

Haiyan He1, Weijun Fu1, Juan Du1, Hua Jiang1, Jian Hou1.   

Abstract

Entities:  

Keywords:  POEMS syndrome; bortezomib; peripheral neuropathy

Mesh：

Substances：

Year:  2017        PMID： 28146276     DOI： 10.1111/bjh.14497

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

2.  Characteristics of 1946 Cases of POEMS Syndrome in Chinese Subjects: A Literature-Based Study.

Authors:  Yong Wang; Li-Bo Huang; Yi-Hua Shi; Huan Fu; Zhen Xu; Guo-Qing Zheng; Yan Wang
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

3.  Treatment and outcomes of POEMS syndrome: changes in the past 20 years.

Authors:  Yan-Ying Yu; Xue-Min Gao; Hao Zhao; Hao Cai; Jun Feng; Lu Zhang; Xin-Xin Cao; Daobin Zhou; Jian Li
Journal:  Blood Cancer J       Date:  2021-08-14       Impact factor: 11.037

Review 4.  Update on the POEMS syndrome.

Authors:  Yu Ri Kim
Journal:  Blood Res       Date:  2022-04-30

5.  Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.

Authors:  Ryutaro Taenaka; Sakurako Shimokawa; Ayako Katayama; Toshihiko Nagao; Teppei Obara; Naoaki Nishimura; Atsushi Tsujimoto; Kentaro Kohno; Kenichi Aoki; Ryosuke Ogawa
Journal:  J Med Case Rep       Date:  2022-08-18

6.  Efficacy of novel agents in patients with nephropathy associated with POEMS syndrome.

Authors:  Shuiqin Cheng; Li Huang; Wenjing Fan; Dandan Liang; Xiaodong Zhu; Song Jiang; Yongchun Ge
Journal:  Int Urol Nephrol       Date:  2022-02-08       Impact factor: 2.266

7.  Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.

Authors:  Tomoki Suichi; Sonoko Misawa; Yukari Sekiguchi; Kazumoto Shibuya; Keigo Nakamura; Hiroki Kano; Yuya Aotsuka; Ryo Otani; Marie Morooka; Shokichi Tsukamoto; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Satoshi Kuwabara
Journal:  Intern Med       Date:  2022-09-01       Impact factor: 1.282

8.  Daratumumab-bortezomib-dexamethasone use in relapsed POEMS syndrome.

Authors:  Jahanzaib Khwaja; Ryan Keh; Duncan Smyth; Michael Peter Lunn; Shirley D'Sa; Jonathan Sive
Journal:  EJHaem       Date:  2022-06-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.